Literature DB >> 29386336

The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis.

David Araújo1, Michal Shteinberg2, Stefano Aliberti3,4, Pieter C Goeminne5,6, Adam T Hill7, Thomas C Fardon8, Dusanka Obradovic9, Glenda Stone10, Marion Trautmann10, Angela Davis10, Katerina Dimakou11, Eva Polverino12, Anthony De Soyza13,14, Melissa J McDonnell14,15, James D Chalmers16.   

Abstract

Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients but it is not known whether it is associated with worse clinical outcomes independent of the underlying severity of disease.This study analysed data from 2596 bronchiectasis patients included from 10 different bronchiectasis clinical centres across Europe and Israel, with a 5-year follow-up period. Prevalence of P. aeruginosa chronic infection and its independent impact on exacerbations, hospitalisations, quality of life and mortality was assessed.The prevalence of P. aeruginosa chronic infection was 15.0% (n=389). P. aeruginosa was associated with a higher mortality in a univariate analysis (hazard ratio (HR) 2.02; 95% (confidence interval) CI 1.53-2.66; p<0.0001) but an independent impact on mortality was not found in a multivariate analysis (HR 0.98; 95% CI 0.70-1.36; p=0.89). P. aeruginosa was independently associated with increased mortality only in patients with frequent exacerbations (two or more per year) (HR 2.03; 95% CI 1.36-3.03; p=0.001). An independent association with worse quality of life of 7.46 points (95% CI 2.93-12.00; p=0.001) was found in a multivariable linear regression. P. aeruginosa was therefore found to be independently associated with exacerbation frequency, hospital admissions and worse quality of life. Mortality was increased in patients with P. aeruginosa particularly in the presence of frequent exacerbations.
Copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 29386336     DOI: 10.1183/13993003.01953-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  35 in total

Review 1.  Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Authors:  Patrick A Flume; James D Chalmers; Kenneth N Olivier
Journal:  Lancet       Date:  2018-09-08       Impact factor: 79.321

2.  Integrative microbiomics in bronchiectasis exacerbations.

Authors:  Micheál Mac Aogáin; Jayanth Kumar Narayana; Pei Yee Tiew; Nur A'tikah Binte Mohamed Ali; Valerie Fei Lee Yong; Tavleen Kaur Jaggi; Albert Yick Hou Lim; Holly R Keir; Alison J Dicker; Kai Xian Thng; Akina Tsang; Fransiskus Xaverius Ivan; Mau Ern Poh; Martina Oriano; Stefano Aliberti; Francesco Blasi; Teck Boon Low; Thun How Ong; Brian Oliver; Yan Hui Giam; Augustine Tee; Mariko Siyue Koh; John Arputhan Abisheganaden; Krasimira Tsaneva-Atanasova; James D Chalmers; Sanjay H Chotirmall
Journal:  Nat Med       Date:  2021-04-05       Impact factor: 53.440

3.  Management of Australian Adults with Bronchiectasis in Tertiary Care: Evidence-Based or Access-Driven?

Authors:  Simone K Visser; Peter T P Bye; Greg J Fox; Lucy D Burr; Anne B Chang; Chien-Li Holmes-Liew; Paul King; Peter G Middleton; Graeme P Maguire; Daniel Smith; Rachel M Thomson; Enna Stroil-Salama; Warwick J Britton; Lucy C Morgan
Journal:  Lung       Date:  2019-11-05       Impact factor: 2.584

4.  Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis.

Authors:  Simon Finch; Irena F Laska; Hani Abo-Leyah; Thomas C Fardon; James D Chalmers
Journal:  Chest       Date:  2019-11-12       Impact factor: 9.410

5.  Exhaled gases and the potential for cross-infection via noninvasive ventilation machines.

Authors:  Benjamin Messer; Alison Dawn Armstrong; Nicholas David Lane; Ali Robb; Robert Edward Bullock
Journal:  ERJ Open Res       Date:  2022-07-04

6.  PsrA Regulator Connects Cell Physiology and Class 1 Integron Integrase Gene Expression Through the Regulation of lexA Gene Expression in Pseudomonas spp.

Authors:  Katarina D Novovic; Milka J Malesevic; Brankica V Filipic; Nemanja L Mirkovic; Marija S Miljkovic; Milan O Kojic; Branko U Jovčić
Journal:  Curr Microbiol       Date:  2019-01-25       Impact factor: 2.188

7.  Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.

Authors:  Yu Lin; Diana Quan; Rachel Yoon Kyung Chang; Michael Y T Chow; Yuncheng Wang; Mengyu Li; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2020-11-27       Impact factor: 5.571

8.  Nutrition and Markers of Disease Severity in Patients With Bronchiectasis.

Authors:  Katherine A Despotes; Radmila Choate; Doreen Addrizzo-Harris; Timothy R Aksamit; Alan Barker; Ashwin Basavaraj; Charles L Daley; Edward Eden; Angela DiMango; Kevin Fennelly; Julie Philley; Margaret M Johnson; Pamela J McShane; Mark L Metersky; Anne E O'Donnell; Kenneth N Olivier; Matthias A Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino; Kevin L Winthrop; Michael R Knowles; Mary Leigh Anne Daniels; Peadar G Noone
Journal:  Chronic Obstr Pulm Dis       Date:  2020-10

9.  Increased Incidence and Associated Risk Factors of Aspergillosis in Patients with Bronchiectasis.

Authors:  Bumhee Yang; Taehee Kim; Jiin Ryu; Hye Yun Park; Bin Hwangbo; Sun-Young Kong; Yong-Soo Kwon; Seung Jun Lee; Seung Won Ra; Yeon-Mok Oh; Jang Won Sohn; Kang Hyeon Choe; Hayoung Choi; Hyun Lee
Journal:  J Pers Med       Date:  2021-05-17

Review 10.  Head-to-head trials of antibiotics for bronchiectasis.

Authors:  Axel Kaehne; Stephen J Milan; Lambert M Felix; Emer Sheridan; Paul A Marsden; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.